Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Study design of URO-12 trial of niraparib as maintenance therapy for advanced urothelial carcinoma

Massimo Di Maio, PhD, University of Turin, Turin, Italy, explains the rationale and study design of the Phase II URO-12 trial (NCT03945084) which investigated the use of niraparib as maintenance therapy for patients with advanced urothelial carcinoma who have undergone first-line platinum-based chemotherapy. After 4-6 rounds of platinum-based chemotherapy, patients in the experimental arm received niraparib until either disease progression or unacceptable levels of toxicity were reached. Patients in the control arm received best supportive care as maintenance therapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Disclosures

Massimo Di Maio reports personal fees from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Janssen, Eisai, Astellas, Merck Sharp & Dohme, Boehringer Ingelheim, research grant from Tesaro – GlaxoSmithKline.